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In the late 1980s, several investigators applied
the strategy of combining genetic engineering
with brain grafting (for review see Gage et al.,
Neuron 1991; 6: 1). Disadvantages associated
with current approaches include the use of non-
brain donor tissue (fibroblasts), the use of
tumor-derived cell lines, and the use of viral
infection methods to introduce the gene of in-
terest. We report here the use of the non-viral,
calcium phosphate transfection method to intro-
duce stably expressed genes into primary
cultures of striatal astrocytes for subsequent use
in brain grafting. Astrocytes may be the pre-
ferred cellular vehicle for gene replacement
therapy in brain transplantation paradigms
because they divide in culture, are brain-derived
and regionally specific, possess a release mecha-
nism, secrete growth factors, can migrate several
millimeters from the transplant site, and have
neurotransmitter receptors. In addition, we
introduce and demonstrate the regulation of
gene product expression by systemically adminis-
tered drugs. Thus, by the incorporation of
inducible promoters in the transfected gene
sequence, drugs which act upon astrocyte neuro-
transmitter receptors can regulate the level of
transfected gene expression.
Neonatal (day 2) rat striatal astrocytes were
transfected with RSV-driven or enkephalin
promoter-driven chloramphenicol acetyl trans-
ferase (CAT) chimeric plasmids after 3 weeks in
culture. In addition, the incorporation of the
neomycin resistance gene combined with selec-
tive growth of transfected cells in G418-
containing (300 /sg/ml) media for 3 additional
weeks insured stable transfected gene incor-
poration from all surviving astrocytes. These cul-
tured astrocytes expressed CAT enzymatic ac-
tivity, which was measured both in cell lysates
and in the conditioned media. As the cells in
these cultures were 100% viable, the latter
observation indicates that the astrocytes
secreted CAT into the media. Following trans-
plantation into the adult rat striatum, the
transplanted astrocytes were identified histologi-
cally by astrocyte-specific GFAP staining, as well
as with antibody staining to CAT protein to
specifically detect the transfected cells. To be
certain that GFAP and CAT staining identified
transplanted cells, CAT activity was also bio-
chemically detected in tissue blocks containing
the transplant at both 1 day and 3 weeks after
transplantation.
Pharmacological regulation of gene product
expression was demonstrated using transfected
astrocytes containing the human prepro-
enkephalin (ppEnk) promoter in the gene
sequence. Regulation of the ppEnk gene by
cAMP-dependent second messenger mecha-
nisms has been studied previously (Comb et al.,
Nature 1986; 323: 353). We studied in vitro the
effect of various dopaminergic and serotonergic
agonists, both of which can act via cAMP path-
ways in astrocytes (Hansson, Prog Neurobiol
1988; 30: 369). Serotonin agonists did not affect
the expression of the transfected gene in striatal
astrocytes. However, dopaminergic receptor
agonists (dopamine, apomorphine, SKF38393,
quinpirole) produced increases in transfected
CAT gene expression in vitro as much as 20-fold
(see Figure, from Weisinger et al., submitted).
This effect was blocked by dopamine anta-
gonists. Regulation of the inducible enkephalin
promoter in astrocyte transplants in vivo has also
been successful. Amphetamine (3 mg/kg, i.p.,
T.I.D.) produced approximately a 2-fold increase
in graft-derived CAT activity. Conversely, grafts
placed in dopamine denervated striata con-
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tained 30% less CAT activity than did grafts in
the intact/contralateral striata. Gene regulation
by drugs would enable transplant protocols to
control the regulation of any transfected gene
product (e.g., growth factors, transmitters,
receptors, etc.) on command during develop-
ment or after brain injury.
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